HK1072254A1 - Pyrrolo pyrimidines as agents for the inhibition of cystein proteases - Google Patents

Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Info

Publication number
HK1072254A1
HK1072254A1 HK05104226A HK05104226A HK1072254A1 HK 1072254 A1 HK1072254 A1 HK 1072254A1 HK 05104226 A HK05104226 A HK 05104226A HK 05104226 A HK05104226 A HK 05104226A HK 1072254 A1 HK1072254 A1 HK 1072254A1
Authority
HK
Hong Kong
Prior art keywords
inhibition
agents
cystein proteases
cathepsin
pyrimidines
Prior art date
Application number
HK05104226A
Other languages
English (en)
Inventor
Betschart Claudia
Hayakawa Kenji
Irie Osamu
Sakaki Junichi
Iwasaki Genji
Lattmann Rene
Missbach Martin
Teno Naoki
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1072254A1 publication Critical patent/HK1072254A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK05104226A 2001-08-30 2005-05-20 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases HK1072254A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121033.5A GB0121033D0 (en) 2001-08-30 2001-08-30 Organic compounds
PCT/EP2002/009663 WO2003020721A1 (en) 2001-08-30 2002-08-29 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Publications (1)

Publication Number Publication Date
HK1072254A1 true HK1072254A1 (en) 2005-08-19

Family

ID=9921234

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104226A HK1072254A1 (en) 2001-08-30 2005-05-20 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases

Country Status (30)

Country Link
US (2) US7452886B2 (ko)
EP (1) EP1423391B8 (ko)
JP (1) JP4629334B2 (ko)
KR (1) KR100695845B1 (ko)
CN (1) CN100372849C (ko)
AR (1) AR036374A1 (ko)
AT (1) ATE326469T1 (ko)
AU (1) AU2002333760B2 (ko)
BR (1) BR0212226A (ko)
CA (1) CA2458684C (ko)
CY (1) CY1105573T1 (ko)
DE (1) DE60211530T2 (ko)
DK (1) DK1423391T3 (ko)
EC (1) ECSP044998A (ko)
ES (1) ES2262888T3 (ko)
GB (1) GB0121033D0 (ko)
HK (1) HK1072254A1 (ko)
HU (1) HUP0401301A3 (ko)
IL (3) IL160367A0 (ko)
MX (1) MXPA04001935A (ko)
MY (1) MY157368A (ko)
NO (1) NO328890B1 (ko)
NZ (1) NZ531343A (ko)
PE (1) PE20030418A1 (ko)
PL (1) PL368280A1 (ko)
PT (1) PT1423391E (ko)
RU (1) RU2331644C2 (ko)
TW (1) TWI297690B (ko)
WO (1) WO2003020721A1 (ko)
ZA (1) ZA200401042B (ko)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
CN1708293A (zh) 2002-09-24 2005-12-14 诺瓦提斯公司 治疗脱髓鞘疾病的鞘氨醇－1－磷酸受体激动剂
AR043692A1 (es) * 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
GB0304640D0 (en) * 2003-02-28 2003-04-02 Novartis Ag Organic compounds
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
EP1797883A3 (en) * 2003-04-28 2007-08-01 Novartis AG Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
WO2004096227A1 (en) * 2003-04-28 2004-11-11 Novartis Ag Pharmaceutical compositon comprising a cathepsin s inhibitor and an opioid
US6987194B2 (en) * 2003-04-30 2006-01-17 Fmc Corporation Insecticidal (dihalopropenyl) phenylalkyl substituted dihydrobenzofuran and dihydrobenzopyran derivatives
WO2005011703A1 (en) * 2003-08-04 2005-02-10 Akzo Nobel N.V. 2-cyano-1,3,5-triazine-4,6-diamine derivatives
EP1786816A4 (en) 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
KR20070027504A (ko) 2004-02-18 2007-03-09 아스트라제네카 아베 테트라졸 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도
WO2005085210A1 (ja) * 2004-03-10 2005-09-15 Ono Pharmaceutical Co., Ltd. ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
AU2005243238B2 (en) * 2004-05-03 2011-11-10 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (SARMS)
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
EP1790639B1 (en) 2004-08-27 2014-03-26 Ono Pharmaceutical Co., Ltd. Spirocyclic compounds and their use as cxcr4-antagonists
KR100651849B1 (ko) * 2005-02-01 2006-12-01 엘지전자 주식회사 세탁기
RU2424234C2 (ru) * 2005-08-05 2011-07-20 Ибриженикс Са Новые ингибиторы цистеиновых протеаз и их терапевтическое применение
US8178083B2 (en) 2005-09-01 2012-05-15 Ares Trading, S.A. Treatment of optic neuritis
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
AR056720A1 (es) * 2005-10-26 2007-10-17 Smithkline Beecham Corp Compuesto de tiazol substtuido composicion farmaceuticamente que lo comprende y su uso para preparar un medicamento
JP5217438B2 (ja) 2005-11-18 2013-06-19 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
WO2007067504A2 (en) * 2005-12-05 2007-06-14 Incyte Corporation Lactam compounds and methods of using the same
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
EP2061775A2 (en) 2006-09-13 2009-05-27 Astra Zeneca AB Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
CN101896480A (zh) 2007-10-19 2010-11-24 阿斯利康(瑞典)有限公司 作为亲代谢性谷氨酸受体(mglurs)调节剂的四唑衍生物
EP3545953A1 (en) 2008-06-20 2019-10-02 Novartis AG Paediatric compositions for treating1 multiple sclerosis
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011082273A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
US9115126B2 (en) 2010-01-15 2015-08-25 Merck Sharp & Dohme B.V. 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US10047398B2 (en) 2010-10-06 2018-08-14 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
CA2846652C (en) 2011-09-02 2019-11-05 Incyte Corporation Heterocyclylamines as pi3k inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
PL2840083T3 (pl) * 2012-04-17 2018-01-31 Astellas Pharma Inc Bicykliczny aromatyczny związek heterocykliczny zawierający azot
JP6386450B2 (ja) 2012-06-06 2018-09-05 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） 肺がん転移の診断、予後診断および処置のための方法
US20140105918A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
CA2906394A1 (en) 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
CA2926894A1 (en) 2013-10-09 2015-04-16 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US10793642B2 (en) 2014-12-11 2020-10-06 Inbiomotion S.L. Binding members for human c-MAF
ES2843522T3 (es) 2015-02-27 2021-07-19 Incyte Corp Sales del inhibidor de PI3K y procesos para su preparación
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
PT3458610T (pt) 2016-05-25 2021-06-29 Inbiomotion Sl Tratamento terapêutico de cancro da mama baseado no estado de c-maf
CN111565725A (zh) 2017-11-22 2020-08-21 生物运动有限公司 基于c-maf状态的乳腺癌的治疗性处理
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
EP4326721A1 (en) * 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270922A (ko) 1960-11-02
CH627919A5 (de) 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
CN1134439C (zh) * 1997-03-19 2004-01-14 艾博特股份有限两合公司 吡咯并[2,3d]嘧啶类化合物及它们作为酪氨酸激酶抑制剂的用途
US6384041B1 (en) * 1998-06-30 2002-05-07 Eli Lilly And Company Bicyclic sPLA2 inhibitors
CA2344249A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines as protein kinase inhibitors
EA006227B1 (ru) * 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
EP1265897A1 (en) * 2000-03-20 2002-12-18 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
EP1277741A4 (en) 2000-04-28 2003-05-07 Tanabe Seiyaku Co CYCLE CONNECTIONS

Also Published As

Publication number Publication date
DK1423391T3 (da) 2006-09-25
AU2002333760B2 (en) 2007-01-04
HUP0401301A3 (en) 2008-03-28
NO20041180L (no) 2004-03-19
CN1549817A (zh) 2004-11-24
RU2331644C2 (ru) 2008-08-20
JP4629334B2 (ja) 2011-02-09
EP1423391B1 (en) 2006-05-17
ECSP044998A (es) 2004-04-28
CA2458684A1 (en) 2003-03-13
IL160367A0 (en) 2004-07-25
NZ531343A (en) 2006-01-27
BR0212226A (pt) 2004-08-17
HUP0401301A2 (hu) 2004-10-28
ZA200401042B (en) 2004-10-25
TWI297690B (en) 2008-06-11
AR036374A1 (es) 2004-09-01
DE60211530D1 (de) 2006-06-22
PL368280A1 (en) 2005-03-21
CN100372849C (zh) 2008-03-05
CY1105573T1 (el) 2010-07-28
US20050054851A1 (en) 2005-03-10
US7452886B2 (en) 2008-11-18
PT1423391E (pt) 2006-09-29
EP1423391A1 (en) 2004-06-02
MY157368A (en) 2016-06-15
IL198643A (en) 2010-12-30
EP1423391B8 (en) 2007-12-12
NO328890B1 (no) 2010-06-07
ES2262888T3 (es) 2006-12-01
PE20030418A1 (es) 2003-06-12
CA2458684C (en) 2009-04-07
JP2005502683A (ja) 2005-01-27
US20090054467A1 (en) 2009-02-26
WO2003020721A1 (en) 2003-03-13
IL160367A (en) 2009-12-24
RU2004109815A (ru) 2005-10-20
GB0121033D0 (en) 2001-10-24
KR20040029123A (ko) 2004-04-03
ATE326469T1 (de) 2006-06-15
KR100695845B1 (ko) 2007-03-20
MXPA04001935A (es) 2004-06-15
DE60211530T2 (de) 2006-12-21

Similar Documents

Publication Publication Date Title
HK1072254A1 (en) Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
PL367821A1 (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
GB0220187D0 (en) Organic compounds
HK1089156A1 (en) Spiro-substituted pyrrolopyrimidines
YU84603A (sh) Novi inhibitori tirozin kinaze
ZA200406813B (en) Glytaminyl based DPIV inhibitors
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
JO2473B1 (en) Pyrazoles as inhibitors of tumor necrosis factor
ZA9810735B (en) Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
WO2001034565A3 (en) Protease inhibitors
WO2001034566A3 (en) Protease inhibitors
MY128242A (en) Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1 and tnf
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma
IL175436A0 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
HRP20030696A2 (en) GlyT-1 INHIBITORS
ECSP044989A (es) Inhibidores de proteasa de cisteina con estructura de 2-ciano-4-amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflamaciones y otras enfermedades

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110829